Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Accardi

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Annals of the New York Academy of Sciences|November 27, 2014
The osteoblastic niche in the context of multiple myelomaDenise Toscani, Marina Bolzoni, Fabrizio Accardi, et al.
Calcified Tissue International|October 30, 2017
The Proteasome and Myeloma-Associated Bone DiseaseFabrizio Accardi, Denise Toscani, Federica Costa, et al.
Journal of Clinical Medicine|September 23, 2020
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple MyelomaBenedetta Dalla Palma, Valentina Marchica, Maria Teresa Catarozzo, et al.
Biomed Research International|November 19, 2015
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingFabrizio Accardi, Denise Toscani, Marina Bolzoni, et al.
Expert Review of Hematology|May 25, 2019
Novel targets for the treatment of relapsing multiple myelomaNicola Giuliani, Fabrizio Accardi, Valentina Marchica, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|July 9, 2026
[Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits (PGNMID) Associated with Marginal Zone B-cell Lymphoma: A Case of MGRS in a Patient with Nephrotic Syndrome and Rapidly Progressive Renal Failure]Luca Visconti, Sebastiano Calimeri, Guido Gembillo, et al.
Leukemia|July 22, 2021
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myelomaJooeun Bae, Fabrizio Accardi, Teru Hideshima, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 10, 2015
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome InhibitorsDenise Toscani, Carla Palumbo, Benedetta Dalla Palma, et al.
Case Reports in Hematology|April 14, 2018
A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading DiagnosisFabrizio Accardi, Valentina Papa, Anna Rita Capozzi, et al.
Hematology Reports|May 4, 2018
Neurofibromatosis type I and multiple myeloma coexistence: A possible link?Fabrizio Accardi, Valentina Marchica, Cristina Mancini, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Annals of the New York Academy of Sciences|November 27, 2014
The osteoblastic niche in the context of multiple myelomaDenise Toscani, Marina Bolzoni, Fabrizio Accardi, et al.
Calcified Tissue International|October 30, 2017
The Proteasome and Myeloma-Associated Bone DiseaseFabrizio Accardi, Denise Toscani, Federica Costa, et al.
Journal of Clinical Medicine|September 23, 2020
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple MyelomaBenedetta Dalla Palma, Valentina Marchica, Maria Teresa Catarozzo, et al.
Biomed Research International|November 19, 2015
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingFabrizio Accardi, Denise Toscani, Marina Bolzoni, et al.
Expert Review of Hematology|May 25, 2019
Novel targets for the treatment of relapsing multiple myelomaNicola Giuliani, Fabrizio Accardi, Valentina Marchica, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|July 9, 2026
[Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits (PGNMID) Associated with Marginal Zone B-cell Lymphoma: A Case of MGRS in a Patient with Nephrotic Syndrome and Rapidly Progressive Renal Failure]Luca Visconti, Sebastiano Calimeri, Guido Gembillo, et al.
Leukemia|July 22, 2021
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myelomaJooeun Bae, Fabrizio Accardi, Teru Hideshima, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 10, 2015
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome InhibitorsDenise Toscani, Carla Palumbo, Benedetta Dalla Palma, et al.
Case Reports in Hematology|April 14, 2018
A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading DiagnosisFabrizio Accardi, Valentina Papa, Anna Rita Capozzi, et al.
Hematology Reports|May 4, 2018
Neurofibromatosis type I and multiple myeloma coexistence: A possible link?Fabrizio Accardi, Valentina Marchica, Cristina Mancini, et al.
Pageof 3